Soligenix Gets FDA's Fast Track Designation For SGX945 For Oral Lesions Of Behçet's Disease

Soligenix, Inc. (SNGX) announced on Monday that its SGX945 or Dusquetide development program for oral lesions of Behçet's Disease has received a 'Fast Track' designation from the FDA.

Related Keywords

,Soligenix Inc ,Fast Track ,Fda ,Soligenix ,Stock Alert ,